Cad clinical trials

Explore recruiting cad clinical trials.

Recruiting cad studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cad trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study

Netherlands, Belgium, Denmark, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease

Poland, Italy, Finland, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention

Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Conditions Using PET Imaging

Denmark, Sweden, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, long-term, safety and tolerability study of SAR445088 in participants with cold agglutinin disease previously treated with SAR445088 or never treated with SAR445088

Germany, Netherlands, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Cad trials by city

Cad in Toronto Cad in Vancouver Cad in Montreal Cad in Calgary Cad in Edmonton Cad in Ottawa Cad in Winnipeg Cad in Quebec City Cad in Hamilton Cad in Kitchener Cad in London Cad in Halifax Cad in New York Cad in Los Angeles Cad in Chicago Cad in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease